AIM ImmunoTech Inc. Company Profile

Background

Overview

AIM ImmunoTech Inc. is an immuno-pharmaceutical company dedicated to the research and development of therapeutics targeting various cancers, viral diseases, and immune-deficiency disorders. Established in 1966 and headquartered in Ocala, Florida, the company has a longstanding commitment to advancing immunology solutions for a better future.

Mission and Vision

AIM ImmunoTech's mission is to develop innovative therapies that enhance the body's immune response against diseases. The company's vision is to become a leader in immuno-pharmaceuticals by providing effective treatments for complex health conditions.

Primary Area of Focus

The company's primary focus is on developing immuno-modulatory therapies, particularly for cancers and immune-related disorders.

Industry Significance

Operating within the biotechnology sector, AIM ImmunoTech contributes to the advancement of immuno-oncology and antiviral treatments, addressing significant unmet medical needs.

Key Strategic Focus

Core Objectives

Advance the clinical development of Ampligen® (rintatolimod) across multiple indications.

Expand the therapeutic applications of its product pipeline.

Establish strategic partnerships to enhance research and development capabilities.

Specific Areas of Specialization

Immuno-oncology

Viral diseases

Immune system disorders

Key Technologies Utilized

Nucleic acid-based immunotherapies

Natural interferon products

Primary Markets Targeted

United States

Europe

Latin America

Financials and Funding

Funding History

AIM ImmunoTech has undergone several funding rounds, including post-IPO equity and debt financing, to support its research and development initiatives. Specific details regarding the total funds raised and recent funding rounds are not publicly disclosed.

Notable Investors

The company has attracted investments from various institutional investors, though specific names are not publicly disclosed.

Utilization of Capital

The capital raised is primarily allocated towards advancing clinical trials, expanding the product pipeline, and strengthening operational capabilities.

Pipeline Development

Key Pipeline Candidates

Ampligen® (rintatolimod): An investigational drug with broad-spectrum activity, currently being evaluated in multiple clinical trials for various cancers, including pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers.

Alferon N Injection® (Interferon alfa): A purified, natural-source, glycosylated, multi-species alpha interferon product approved for the treatment of genital warts.

Stages of Clinical Trials

Ampligen® is in various stages of clinical trials, including Phase 2 studies for pancreatic cancer and evaluations for other solid tumors.

Target Conditions

Cancers

Viral diseases

Immune system disorders

Anticipated Milestones

Completion of ongoing clinical trials

Regulatory submissions for new indications

Technological Platform and Innovation

Proprietary Technologies

Nucleic acid-based immunotherapies

Natural interferon products

Significant Scientific Methods

Clinical trial methodologies

Immunological assays

Leadership Team

Key Executives

Thomas K. Equels Esq., J.D., M.S.: Executive Vice Chairman, Chief Executive Officer, and President. Mr. Equels has extensive experience in the pharmaceutical industry, leading AIM ImmunoTech since 2019.

Robert Dickey IV, B.A., M.B.A.: Chief Financial Officer. Mr. Dickey brings a strong financial background to the company, overseeing financial operations and strategy.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in immuno-oncology and antiviral treatments, is experiencing rapid growth, driven by advancements in personalized medicine and increasing demand for innovative therapies.

Competitor Analysis

NexImmune: Focuses on developing immune-modulating therapies for cancer treatment.

Aura: Specializes in immuno-oncology treatments targeting various cancers.

Jounce Therapeutics: Develops immunotherapies aimed at enhancing the body's immune response against tumors.

Strategic Collaborations and Partnerships

AIM ImmunoTech collaborates with renowned university partners to fund and advance its clinical studies, leveraging academic expertise to enhance research outcomes.

Operational Insights

AIM ImmunoTech's strategic focus on immuno-oncology and antiviral treatments positions it to address significant unmet medical needs, differentiating it from competitors through its specialized product pipeline and research collaborations.

Strategic Opportunities and Future Directions

The company aims to expand its clinical trials, seek regulatory approvals for new indications, and explore additional strategic partnerships to enhance its market presence and therapeutic offerings.